Public consultation for the 2016 evaluation of the EU Drugs Strategy and Action Plan on Drugs

Fields marked with * are mandatory.

* Please choose from one of the following options on the use of your contribution:

- My contribution can be directly published, with my personal/organisation information (I consent to publication of all information in my contribution in whole or in part including my name/the name of my organisation, and I declare that nothing within my response is unlawful or would infringe the rights of any third party in a manner that would prevent publication).

- My contribution can be directly published, provided that this is done anonymously. (I consent to publication of any information in my contribution in whole or in part (which may include quotes or opinions I express, and I declare that nothing within my response is unlawful or would infringe the rights of any third party in a manner that would prevent publication).

- My contribution cannot be directly published but may be included within statistical data (I understand that my contribution will not be directly published, but that my anonymised responses may be included in published statistical data). Note that your answers may be subject to a request for public access to documents under Regulation (EC) No 1049/2001.

* If required, can the Commission services contact you for further details on the information you have submitted?

- Yes
- No
1. Are you submitting your contribution as:

Only one choice is possible

- a private individual
- a national public authority
- an international/intergovernmental/regional organisation
- an organisation (non-governmental, civil society organisation, academia, research, social partner, interest group, consultancy, think-tank…) or private company

Is your organisation registered in the Transparency Register?

- Yes
- No. If you would like to register now, please click here. If you decide not to register, your answers will be listed separately as part of the individual contributions.

2. Please, provide your name and/or your organisation's name and contact details:

200 character(s) maximum

Cooperativa sociale Open Group,
partita iva 02410141200
CCIAABologna REA 437561
iscrizione albo società cooperative A108662
Mura di Porta Galliera 1/2 A
40126 Bologna
telefono 051242557

3. The answers you will provide are expected to refer to a specific Member State or to the EU as a whole. Please, select the option that best fits your case:

Italy

4. Please specify your level of involvement in the area of drug policy:

- I am actively working in the field
- I am interested in the field without actively working in it
Please explain your involvement:

Only one choice is possible

- Official of public institutions active in the field (Ministry of Justice, Health and Social Affairs, Interior, etc.)
- Healthcare professional (doctor, nurse, psychologist etc.)
- Journalist
- Law enforcement representative
- NGO member
- Policy maker
- Researcher or academic
- Social worker
- Other

5. Which of the following areas of drug-related policies best describes your field of activity or interest?

Multiple answer options can be selected

- Drug demand reduction
- Drug supply reduction
- Coordination of drug policies at international/EU level
- Coordination of drug policies at regional/national level
- Cooperation with non-EU countries and international organisations
- Information, research, monitoring and evaluation activities
- Other

6. Did you take part in any activity related to the selected policy area(s) in the period 2013-2016?

Multiple answer options can be selected

- no
- yes, in the definition of drug-related policies and/or legislation
- yes, in the implementation of drug-related policies and/or legislation
- yes, in the monitoring of drug-related policies and/or legislation
- yes, in the evaluation of drug-related policies and/or legislation factors

7. In your opinion, in the period 2013-2016 were measures implemented with the aim of:
<table>
<thead>
<tr>
<th>Action</th>
<th>YES</th>
<th>NO</th>
<th>NO OPINION</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Delaying the first use of drugs</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Preventing drug use by people with age, gender, cultural or social risk factors (e.g. through initiatives for children and teenagers in the schools, pregnant women, Roma population)</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Preventing drug use by people with situational risk factors (e.g. homelessness, working and driving under the influence of drugs, drugs use in nightlife)</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Preventing drug use by people with individual risk factors (e.g. multiple addictions, mental health problems, family circumstances)</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Raising awareness on the misuse of and dependence on medicines</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Increasing the availability of drug treatment and rehabilitation services</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Increasing the accessibility of drug treatment and rehabilitation services</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Introducing best practices and quality approaches in drug demand reduction</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Reducing drug-related risk and harm (e.g. prevention of infectious diseases such as HIV, hepatitis C)</em></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
8. In your opinion, to what extent has the effectiveness* of these measures changed during the period 2013-2016 compared to the period 2005-2012?

* Effectiveness: to what extent EU/national actions have achieved the expected results or contributed to progress in certain areas.

<table>
<thead>
<tr>
<th>Measure</th>
<th>IT IMPROVED</th>
<th>IT REMAINED THE SAME</th>
<th>IT GOT WORSE</th>
<th>NO OPINION</th>
</tr>
</thead>
<tbody>
<tr>
<td>*Delay of the first use of drugs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Prevention of drugs use by people with age, gender, cultural or social risk factors (e.g. through initiatives for children and teenagers in the schools, pregnant women, Roma population)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Prevention of drugs use by people with situational risk factors (e.g. homelessness, working and driving under the influence of drugs, drugs use in nightlife)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Prevention of drugs use by people with individual risk factors (e.g. other addictions, mental health problems, family circumstances)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Awareness on the misuse of and dependence on medicines</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Availability and accessibility of treatment and rehabilitation services</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
9. In your opinion, what steps could be taken to improve the effectiveness of the drug demand reduction policies in the EU?

Multiple answer options can be selected

- Adoption of more binding provisions and commitments at a national/regional level
- Development of deeper synergies between the EU and national measures
- Improvement of research, monitoring, collecting data and evaluation activity
- Stronger civil society and scientific community involvement
- Allocation of additional financial resources
- Other

If you answered "improvement of research, monitoring, collecting data and evaluation activity", please specify:

- at EU level
- at national level
- at local level

If you answered "stronger civil society and scientific community involvement", please specify:

- at EU level
- at national level
- at local level

If you answered "allocation of additional financial resources", please specify:

- at EU level
- at national level
- at local level
In order to:

- create, improve and evaluate drug prevention programmes
- promote best practices and quality approaches to the drug phenomenon
- create, improve and evaluate targeted and diversified treatment programmes
- improve access to risk and harm reduction services

10. In your opinion, in the period 2013-2016 were measures implemented with the aim of:

<table>
<thead>
<tr>
<th>Measure</th>
<th>YES</th>
<th>NO</th>
<th>NO OPINION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Countering cross-border drug trafficking through the improvement of border security (e.g. in the airports or seaports)</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Increasing legislative and judicial cooperation against cross-border illicit drug activities</td>
<td>☐</td>
<td>☒</td>
<td>☐</td>
</tr>
<tr>
<td>Preventing the diversion and illicit use of drug precursors</td>
<td>☐</td>
<td>☐</td>
<td>☒</td>
</tr>
<tr>
<td>Countering the emergence, use and spread of new psychoactive substances</td>
<td>☐</td>
<td>☐</td>
<td>☒</td>
</tr>
<tr>
<td>Developing sanctions other than detention for drug-using offenders (e.g. rehabilitation, social integration or education)</td>
<td>☒</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Responding to the use of new technologies in illicit drug activities (e.g. purchasing drugs online)</td>
<td>☒</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>
11. In your opinion, to what extent has the effectiveness* of these measures changed during the period 2013-2016 compared to 2005-2012?

* Effectiveness: to what extent EU/national actions have achieved the expected results or contributed to progress in certain areas.

<table>
<thead>
<tr>
<th>Measure</th>
<th>IT IMPROVED</th>
<th>IT REMAINED THE SAME</th>
<th>IT GOT WORSE</th>
<th>NO OPINION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Counter cross-border drug trafficking through the improvement of border security (e.g. in the airports or seaports)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increase of legislative and judicial cooperation against cross-border illicit drug activities</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prevention of the diversion and illicit use of drug precursors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contrast to the emergence, use and spread of new psychoactive substances</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Development of sanctions other than detention for drug-using offenders (e.g. rehabilitation, social integration or education)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Response to the use of new technologies in illicit drug activities (e.g. purchasing drugs online)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
12. In your opinion, what steps could be taken to improve the effectiveness of drug supply reduction policies in the EU?

Multiple answer options can be selected

- Adoption of more binding provisions and commitments at a national/regional level
- Development of deeper synergies between the EU and national measures
- Strengthening of the support to third countries in addressing drug-related organised crime
- Improvement of research, monitoring, collecting data and evaluation activity in the drugs field
- Stronger civil society and scientific community involvement
- Stronger involvement of industry and economic operators in preventing diversion of drug precursors
- Allocation of additional financial resources
- Other

If you answered "improvement of research, monitoring, collecting data and evaluation activity", please specify:

- at international level
- at EU level
- at national level
- at local level

If you answered "stronger civil society and scientific community involvement", please specify:

- at international level
- at EU level
- at national level
- at local level

If you answered "allocation of additional financial resources", please specify:

- for the benefit of third countries known as major drugs suppliers
- at EU level
- at national level
- at local level
In order to:

- identify the emerging trends and threats associated with drug-related crime
- promptly respond to the emerging threats in illicit drug activities
- enhance law enforcement and judicial cooperation

13. In your opinion, in the period 2013-2016 were measures implemented with aim of:

<table>
<thead>
<tr>
<th>Measure</th>
<th>YES</th>
<th>NO</th>
<th>NO OPINION</th>
</tr>
</thead>
<tbody>
<tr>
<td>* Coordinating drug policies and responses at a national level</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Involving the civil society and the scientific community in the development and implementation of drug policies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Cooperating with international organisations in the drug policies field</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Cooperating with non-EU countries in the drug policies field</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>* Information, research, monitoring and evaluation related to the drug phenomenon</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
14. In your opinion, to what extent has the effectiveness* of the following actions changed during the period 2013-2016 compared to 2005-2012?

* Effectiveness: to what extent EU/national actions have achieved the expected results or contributed to progress in certain areas.

<table>
<thead>
<tr>
<th>Action</th>
<th>IT IMPROVED</th>
<th>IT REMAINED THE SAME</th>
<th>IT GOT WORSE</th>
<th>NO OPINION</th>
</tr>
</thead>
<tbody>
<tr>
<td>*Coordination of drug policies and responses at a national level</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Involvement of the civil society and the scientific community in the development and implementation of drug policies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Investments in research, data collection, monitoring, evaluation and information exchange</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Dissemination of research, monitoring and evaluation results</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Cooperation with international organisations in the drug policies field</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Cooperation with third countries in the drug policies field</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Visibility of the EU approach to drugs policy in the international arena</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
15. In your opinion, what steps could be taken to improve the effectiveness of the EU international engagement in the drugs field?

Multiple answer options can be selected

- ✔ Further integration of drug policies within the overall EU common and security foreign policy
- ✔ Enhance dialogue with third countries and regional organisations on tackling drugs, including drug and drug precursors trafficking and drug demand reduction
- ✔ Review the priority countries for EU engagement on drugs with third countries
- ✔ Enhance coordination of EU positions on drug policy with selected countries at UN level
- ✔ Increase financial assistance for drug related cooperation (drug demand reduction and drug supply reduction) programmes with third countries
- ✔ Increase the synergy between policy dialogue and financial assistance on drug policies
- ✔ Mainstream alternative development into EU development programmes with third countries
- ✔ Further explore the links between drugs trafficking and other forms of international organised crime (e.g. terrorism, human trafficking, smuggling,…)
- ✔ Provide for increased EU funding to alternative development programmes
16. In your opinion, what is the EU Drugs Strategy's added value? Please indicate how much you agree with the following statements, on a scale from 1 to 4, where 1 means "I do not agree at all" and 4 means "I fully agree".

<table>
<thead>
<tr>
<th>Statement</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>*It supports the development of a dialogue and/or a consistent approach to drugs at national level</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*It helps to raise important debates on drug policies on the international agenda</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*It helps to improve coherence between national/regional and European drug-related actions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*It facilitates the allocation of a larger amount of national public resources to specific activities or initiatives in the drug field</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*It helps to improve the involvement of civil society and scientific community in drug policies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*The Strategy has no significant added value</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
17. In the future, where do you see the focus of the EU's drugs policy?

* at most 5 choice(s) *

- Prevention
- Treatment and rehabilitation services
- Risk and harm reduction
- Finding synergies between drugs use and other addictions (e.g. alcohol, tobacco, gambling) and addressing them altogether
- Fighting against drugs trafficking, drug precursors diversion and other kinds of organised crime
- Analysing the links between drug trafficking and other major and serious crimes
- Tackling online trade of drugs
- Reinforcing the EU and international response to the spread of new psychoactive substances
- Coordination of drug policies at EU and national/regional/local levels
- Stronger involvement of the EU in addressing world drug challenges
- Strengthening cooperation with non-EU countries and international organisations on drug policies (on both drug demand and drug supply reduction)
- Strengthen the promotion of EU values and approaches
- Promotion of scientific research on drugs
- Monitoring, evaluation, data collection, information and best practices exchange
- Address cannabis at EU level
- I don't think there is a need for future EU action in this domain
- Other

18. Please explain your reasoning for your answer to question 17.

600 character(s) maximum

Because we are agree with the four pillars approach to drug addiction, and we are convinced that the scientific research need more promotion in order to reach civil society and influence policies.

Contact

Alina.RADU@ec.europa.eu